切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 14 ›› Issue (04) : 646 -653. doi: 10.3877/cma.j.issn.2095-3232.2025.04.023

综述

粪菌移植在肝胆胰外科领域研究进展
何勇飞1,2, 王继才1, 吴芬芳1,3, 史宪杰1,†()   
  1. 1518033　深圳，中山大学附属第八医院肝胆胰外科
    2530021　南宁，广西医科大学第一附属医院肝胆外科
    3518172　深圳，北京中医药大学深圳医院
  • 收稿日期:2025-02-12 出版日期:2025-08-10
  • 通信作者: 史宪杰
  • 基金资助:
    中国博士后科学基金(2023M744020); 深圳市基础研究重点项目(JCYJ20220818103407016); 深圳市基础研究资助项目(JCYJ20220530144404011); 深圳市福田区卫生健康系统科研项目(FTWS2023037)

Research progress in fecal microbiota transplantation in hepatobiliary and pancreatic surgery

Yongfei1 He2, Jicai Wang1, Fenfang1 Wu3, Xianjie Shi1,†()   

  1. 1Department of Hepatobiliary and Pancreatic Surgery, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen 518033, China
    2Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
    3Shenzhen Hospital of Beijing University of Chinese Medicine, Shenzhen 518172, China
  • Received:2025-02-12 Published:2025-08-10
  • Corresponding author: Xianjie Shi
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

何勇飞, 王继才, 吴芬芳, 史宪杰. 粪菌移植在肝胆胰外科领域研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 646-653.

Yongfei1 He, Jicai Wang, Fenfang1 Wu, Xianjie Shi. Research progress in fecal microbiota transplantation in hepatobiliary and pancreatic surgery[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(04): 646-653.

肠道微生物群的失衡与肝胆胰疾病的发生、发展和预后有密切的关系，而肝胆胰疾病可以引起肠道微生物群的失衡，两者互相影响、互相作用。粪菌移植（FMT）是重建肠道微生物群，改善肝胆胰疾病预后潜在有效的方法。近年来，FMT在多项临床试验中受到高度重视，已逐步在肝胆胰疾病领域开展临床研究。本文探讨肠道微生物群与肝胆胰疾病的关系，综述FMT在肝胆胰疾病的研究进展。

关键词: 粪便微生物群移植, 肝胆胰疾病, 肠道微生物群, 肠肝轴, 非酒精性脂肪性肝病

The imbalance of gut microbiota is closely correlated with the incidence, development and prognosis of hepatobiliary and pancreatic diseases, which can cause the imbalance of gut microbiota. These two events affect and interact with each other. Fecal microbiota transplantation (FMT) is a promising method to reconstruct gut microbiota and improve prognosis of hepatobiliary and pancreatic diseases. In recent years, FMT has received widespread attention in multiple clinical trials, and has been gradually applied in clinical research of hepatobiliary and pancreatic diseases. In this article, the relationship between gut microbiota and hepatobiliary and pancreatic diseases was illustrated, and research progress in the application of FMT in hepatobiliary and pancreatic diseases was summarized.

Key words: Fecal microbiota transplantation, Liver diseases, Intestinal microbiota, Gut-liver axis, Nonalcoholic fatty liver disease (NAFLD)
[1]
Allegretti JR, Mullish BH, Kelly C, et al. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications[J]. Lancet, 2019, 394(10196): 420-431. DOI: 10.1016/S0140-6736(19)31266-8.
[2]
David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature, 2014, 505(7484): 559-563. DOI: 10.1038/nature12820.
[3]
Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease[J]. FEBS J, 2020, 287(5): 833-855. DOI: 10.1111/febs.15217.
[4]
Motiani KK, Carmen Collado M, Eskelinen JJ, et al. Exercise training modulates gut microbiota profile and improves endotoxemia[J]. Med Sci Sports Exerc, 2020, 52(1): 94-104. DOI: 10.1249/MSS.0000000000002112.
[5]
Walrath T, Dyamenahalli KU, Hulsebus HJ, et al. Age-related changes in intestinal immunity and the microbiome[J]. J Leukoc Biol, 2021, 109(6): 1045-1061. DOI: 10.1002/JLB.3RI0620-405RR.
[6]
Hoefert B. über die bakterienbefunde im duodenalsaft von gesunden und kranken[J]. Zschr Klin Med, 1921, 92, 221-235.
[7]
Zeng Y, Chen S, Fu Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27(2): 143-155. DOI: 10.1111/jvh.13216.
[8]
Schwan A, Sjölin S, Trottestam U, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces[J]. Lancet, 1983, 2(8354): 845. DOI: 10.1016/s0140-6736(83)90753-5.
[9]
Wu Z, Zhang B, Chen F, et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: a randomized, controlled, prospective study[J]. Front Cell Infect Microbiol, 2023, 12: 1089991. DOI: 10.3389/fcimb.2022.1089991.
[10]
Pande A, Sharma S, Khillan V, et al. Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial[J]. Hepatol Int, 2023, 17(1): 249-261. DOI: 10.1007/s12072-022-10438-0.
[11]
Routy B, Lenehan JG, Miller WH Jr, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial[J]. Nat Med, 2023, 29(8): 2121-2132. DOI: 10.1038/s41591-023-02453-x.
[12]
Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome[J]. Science, 2006, 312(5778): 1355-1359. DOI: 10.1126/science.1124234.
[13]
Salvucci E. The human-microbiome superorganism and its modulation to restore health[J]. Int J Food Sci Nutr, 2019, 70(7): 781-795. DOI: 10.1080/09637486.2019.1580682.
[14]
Kastl AJ Jr, Terry NA, Wu GD, et al. The structure and function of the human small intestinal microbiota: current understanding and future directions[J]. Cell Mol Gastroenterol Hepatol, 2020, 9(1): 33-45. DOI: 10.1016/j.jcmgh.2019.07.006.
[15]
Visconti A, Le Roy CI, Rosa F, et al. Interplay between the human gut microbiome and host metabolism[J]. Nat Commun, 2019, 10(1): 4505. DOI: 10.1038/s41467-019-12476-z.
[16]
Postler TS, Ghosh S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system[J]. Cell Metab, 2017, 26(1): 110-130. DOI: 10.1016/j.cmet.2017.05.008.
[17]
Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 397-411. DOI: 10.1038/s41575-018-0011-z.
[18]
Sidhu M, van der Poorten D. The gut microbiome[J]. Aust Fam Physician, 2017, 46(4): 206-211.
[19]
Gupta A, Khanna S. Fecal microbiota transplantation[J]. Jama, 2017, 318(1): 102. DOI: 10.1001/jama.2017.6466.
[20]
Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice[J]. Gut, 2017, 66(4): 569-580. DOI: 10.1136/gutjnl-2016-313017.
[21]
Zhang F, Zhang T, Zhu H, et al. Evolution of fecal microbiota transplantation in methodology and ethical issues[J]. Curr Opin Pharmacol, 2019, 49: 11-16. DOI: 10.1016/j.coph.2019.04.004.
[22]
Biazzo M, Deidda G. Fecal microbiota transplantation as new therapeutic avenue for human diseases[J]. J Clin Med, 2022, 11(14): 4119. DOI: 10.3390/jcm11144119.
[23]
Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial[J]. JAMA, 2017, 318(20): 1985-1993. DOI: 10.1001/jama.2017.17077.
[24]
Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections[J]. Am J Gastroenterol, 2013, 108(4): 478-498;quiz499. DOI: 10.1038/ajg.2013.4.
[25]
de Vos WM, Tilg H, Van Hul M, et al. Gut microbiome and health: mechanistic insights[J]. Gut, 2022, 71(5): 1020-1032. DOI: 10.1136/gutjnl-2021-326789.
[26]
Halsey TM, Thomas AS, Hayase T, et al. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis[J]. Sci Transl Med, 2023, 15(700): eabq4006. DOI: 10.1126/scitranslmed.abq4006.
[27]
Spreafico A, Heirali AA, Araujo DV, et al. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)[J]. Ann Oncol, 2023, 34(6): 520-530. DOI: 10.1016/j.annonc.2023.02.011.
[28]
Yang Q, Wang B, Zheng Q, et al. A review of gut microbiota-derived metabolites in tumor progression and cancer therapy[J]. Adv Sci, 2023, 10(15): e2207366. DOI: 10.1002/advs.202207366.
[29]
Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development[J]. J Hepatol, 2019, 71(6): 1216-1228. DOI: 10.1016/j.jhep.2019.08.005.
[30]
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003.
[31]
Saitta C, Pollicino T, Raimondo G. Occult hepatitis B virus infection: an update[J]. Viruses, 2022, 14(7): 1504. DOI: 10.3390/v14071504.
[32]
You H, Wang F, Li T, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)[J]. J Clin Transl Hepatol, 2023, 11(6): 1425-1442. DOI: 10.14218/JCTH.2023.00320.
[33]
Zhang Q, Zhou J, Zhang X, et al. Mendelian randomization supports causality between gut microbiota and chronic hepatitis B[J]. Front Microbiol, 2023, 14: 1243811. DOI: 10.3389/fmicb.2023.1243811.
[34]
Ren YD, Ye ZS, Yang LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy[J]. Hepatology, 2017, 65(5): 1765-1768. DOI: 10.1002/hep.29008.
[35]
Chauhan A, Kumar R, Sharma S, et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients: a pilot study[J]. Dig Dis Sci, 2021, 66(3): 873-880. DOI: 10.1007/s10620-020-06246-x.
[36]
Guo W, Zhou X, Li X, et al. Depletion of gut microbiota impairs gut barrier function and antiviral immune defense in the liver[J]. Front Immunol, 2021, 12: 636803. DOI: 10.3389/fimmu.2021.636803.
[37]
Wang J, Zhou X, Li X, et al. Fecal microbiota transplantation alters the outcome of hepatitis B virus infection in mice[J]. Front Cell Infect Microbiol, 2022, 12: 844132. DOI: 10.3389/fcimb.2022.844132.
[38]
Wang J, Wang Y, Zhang X, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients[J]. Front Microbiol, 2017, 8: 2222. DOI: 10.3389/fmicb.2017.02222.
[39]
Yun Y, Chang Y, Kim HN, et al. Alterations of the gut microbiome in chronic hepatitis B virus infection associated with alanine aminotransferase level[J]. J Clin Med, 2019, 8(2): 173. DOI: 10.3390/jcm8020173.
[40]
Shen Y, Wu SD, Chen Y, et al. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response[J]. Gut Microbes, 2023, 15(1): 2155018. DOI: 10.1080/19490976.2022.2155018.
[41]
Bajaj JS. Alcohol, liver disease and the gut microbiota[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 235-246. DOI: 10.1038/s41575-018-0099-1.
[42]
Zhang D, Liu Z, Bai F. Roles of gut microbiota in alcoholic liver disease[J]. Int J Gen Med, 2023, 16: 3735-3746. DOI: 10.2147/IJGM.S420195.
[43]
Ciocan D, Voican CS, Wrzosek L, et al. Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis[J]. Aliment Pharmacol Ther, 2018, 48(9): 961-974. DOI: 10.1111/apt.14949.
[44]
Smirnova E, Puri P, Muthiah MD, et al. Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity[J]. Hepatology, 2020, 72(1): 271-286. DOI: 10.1002/hep.31178.
[45]
Wrzosek L, Ciocan D, Hugot C, et al. Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury[J]. Gut, 2021, 70(7): 1299-1308. DOI: 10.1136/gutjnl-2020-321565.
[46]
Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study[J]. Clin Gastroenterol Hepatol, 2017, 15(4): 600-602. DOI: 10.1016/j.cgh.2016.10.029.
[47]
Philips CA, Phadke N, Ganesan K, et al. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis[J]. Indian J Gastroenterol, 2018, 37(3): 215-225. DOI: 10.1007/s12664-018-0859-4.
[48]
Bajaj JS, Gavis EA, Fagan A, et al. A randomized clinical trial of fecal microbiota transplant for alcohol use disorder[J]. Hepatology, 2021, 73(5): 1688-1700. DOI: 10.1002/hep.31496.
[49]
Wong VW, Ekstedt M, Wong GL, et al. Changing epidemiology, global trends and implications for outcomes of NAFLD[J]. J Hepatol, 2023, 79(3): 842-852. DOI: 10.1016/j.jhep.2023.04.036.
[50]
Shou D, Luo Q, Tang W, et al. Hepatobiliary and pancreatic: multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota[J]. J Gastroenterol Hepatol, 2023, 38(12): 2195-2205. DOI: 10.1111/jgh.16359.
[51]
Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep, 2017, 7(1): 1529. DOI: 10.1038/s41598-017-01751-y.
[52]
Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial[J]. Am J Gastroenterol, 2020, 115(7): 1055-1065. DOI: 10.14309/ajg.0000000000000661.
[53]
Xue L, Deng Z, Luo W, et al. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial[J]. Front Cell Infect Microbiol, 2022, 12: 759306. DOI: 10.3389/fcimb.2022.759306.
[54]
Famouri F, Shariat Z, Hashemipour M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents[J]. J Pediatr Gastroenterol Nutr, 2017, 64(3): 413-417. DOI: 10.1097/MPG.0000000000001422.
[55]
Schwabe RF, Greten TF. Gut microbiome in HCC - mechanisms, diagnosis and therapy[J]. J Hepatol, 2020, 72(2): 230-238. DOI: 10.1016/j.jhep.2019.08.016.
[56]
Huang H, Ren Z, Gao X, et al. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma[J]. Genome Med, 2020, 12(1): 102. DOI: 10.1186/s13073-020-00796-5.
[57]
Sun L, Ke X, Guan A, et al. Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery[J]. Clin Transl Med, 2023, 13(7): e1331. DOI: 10.1002/ctm2.1331.
[58]
Behary J, Amorim N, Jiang XT, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma[J]. Nat Commun, 2021, 12(1): 187. DOI: 10.1038/s41467-020-20422-7.
[59]
Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360(6391): eaan5931. DOI: 10.1126/science.aan5931.
[60]
Li Z, Zhang Y, Hong W, et al. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma via STING signaling[J]. Gut Microbes, 2022, 14(1): 2119055. DOI: 10.1080/19490976.2022.2119055.
[61]
Hu C, Xu B, Wang X, et al. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC[J]. Hepatology, 2023, 77(1): 48-64. DOI: 10.1002/hep.32449.
[62]
Spanu D, Pretta A, Lai E, et al. Hepatocellular carcinoma and microbiota: implications for clinical management and treatment[J]. World J Hepatol, 2022, 14(7): 1319-1332. DOI: 10.4254/wjh.v14.i7.1319.
[63]
Mao J, Wang D, Long J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers[J]. J Immunother Cancer, 2021, 9(12): e003334. DOI: 10.1136/jitc-2021-003334.
[64]
Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J]. J Immunother Cancer, 2019, 7(1): 193. DOI: 10.1186/s40425-019-0650-9.
[65]
Lee PC, Wu CJ, Hung YW, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2022, 10(6): e004779. DOI: 10.1136/jitc-2022-004779.
[66]
Kao D, Roach B, Park H, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy[J]. Hepatology, 2016, 63(1): 339-340. DOI: 10.1002/hep.28121.
[67]
Bajaj JS, Kakiyama G, Savidge T, et al. Antibiotic-associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant[J]. Hepatology, 2018, 68(4): 1549-1558. DOI: 10.1002/hep.30037.
[68]
Bajaj JS, Salzman N, Acharya C, et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis[J]. JCI Insight, 2019, 4(24): e133410. DOI: 10.1172/jci.insight.133410.
[69]
Tun KM, Hong AS, Batra K, et al. A systematic review of the efficacy and safety of fecal microbiota transplantation in the treatment of hepatic encephalopathy and Clostridioides difficile infection in patients with cirrhosis[J]. Cureus, 2022, 14(5): e25537. DOI: 10.7759/cureus.25537.
[70]
Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis[J].N Engl J Med, 2016, 375(12): 1161-1170. DOI: 10.1056/NEJMra1506330.
[71]
Tabibian JH, O’Hara SP, Trussoni CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis[J]. Hepatology, 2016, 63(1): 185-196. DOI: 10.1002/hep.27927.
[72]
Bajaj JS, Ann Hays R. Manipulation of the gut-liver axis using microbiome restoration therapy in primary sclerosing cholangitis[J]. Am J Gastroenterol, 2019, 114(7): 1027-1029. DOI: 10.14309/ajg.0000000000000191.
[73]
Philips CA, Augustine P, Phadke N. Healthy donor fecal microbiota transplantation for recurrent bacterial cholangitis in primary sclerosing cholangitis: a single case report[J]. J Clin Transl Hepatol, 2018, 6(4): 438-441. DOI: 10.14218/JCTH.2018.00033.
[74]
Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial[J]. Am J Gastroenterol, 2019, 114(7): 1071-1079. DOI: 10.14309/ajg.0000000000000115.
[75]
段建峰, 刘晓晨, 赵喜荣, 等. 经灌肠途径粪菌移植治疗复杂胆道术后胆瘘继发感染16例[J]. 中国现代普通外科进展, 2019, 22(11): 900-901, 904. DOI: 10.3969/j.issn.1009-9905.2019.11.018.
[76]
李胜兵, 刘海鸿, 黄潮, 等. 粪菌移植在临床治疗中的研究进展[J]. 中国微生态学杂志, 2019, 31(3): 352-355. DOI: 10.13381/j.cnki.cjm.201903023.
[77]
罗旭娟, 白雪, 李增晖, 等. 粪菌移植与中药大黄治疗高脂血症性急性胰腺炎大鼠模型的效果比较[J]. 临床肝胆病杂志, 2022, 38(12): 2767-2773. DOI: 10.3969/j.issn.1001-5256.2022.12.016.
[78]
黄瑞萍. 重症急性胰腺炎肠功能障碍病人粪菌移植治疗的护理[J]. 全科护理, 2017, 15(27): 3371-3372. DOI: 10.3969/j.issn.1674-4748.2017.27.014.
[79]
杨加琦. 追踪肿瘤局部免疫与肠道菌群动态演变探索胰腺癌免疫治疗优化策略[D]. 杭州: 浙江大学, 2020. DOI: 10.27461/d.cnki.gzjdx.2020.002120.
[80]
Nazmul Huda M, Kim M, Bennett BJ. Modulating the microbiota as a therapeutic intervention for type 2 diabetes[J]. Front Endocrinol, 2021, 12: 632335. DOI: 10.3389/fendo.2021.632335.
[81]
Wang Y, Yang Z, Tang H, et al. Faecal microbiota transplantation is better than probiotics for tissue regeneration of type 2 diabetes mellitus injuries in mice[J]. Arch Physiol Biochem, 2024, 130(3): 333-341. DOI: 10.1080/13813455.2022.2080229.
[82]
Wang H, Lu Y, Yan Y, et al. Promising treatment for type 2 diabetes: fecal microbiota transplantation reverses insulin resistance and impaired islets[J]. Front Cell Infect Microbiol, 2020, 9: 455. DOI: 10.3389/fcimb.2019.00455.
[83]
周迎, 李阳阳, 刘煜. 粪菌移植对非肥胖糖尿病小鼠发生1型糖尿病的影响及其机制探讨[J]. 中华医学杂志, 2022, 102(16):1224-1231. DOI: 10.3760/cma.j.cn112137-20210907-02043.
[84]
Plaza-Díaz J, Fontana L, álvarez-Mercado AI. Editorial: interplay between gut microbiota and the immune system in liver surgery and liver diseases[J]. Front Cell Infect Microbiol, 2023, 13: 1188092. DOI: 10.3389/fcimb.2023.1188092.
[85]
胥华泰, 应培均, 杨季红, 等. 肠道菌群对肝癌作用机制的研究进展[J]. 中国临床研究,2024, 37(6): 943-945. DOI: 10.13429/j.cnki.cjcr.2024.06.026.
[86]
周熙祥, 伍志伟, 张录梅, 等. 肠道菌群与肝癌的研究进展[J]. 中国微生态学杂志, 2021, 33(8): 971-975. DOI: 10.13381/j.cnki.cjm.202108022.
[87]
Janket SJ, Ackerson LK, Diamandis EP. Potential risks in fecal microbiota transplantation[J]. Clin Chem Lab Med, 2020, 58(4): e95. DOI: 10.1515/cclm-2019-1076.
[1] 郝玥萦, 毛盈譞, 张羽, 汪佳旭, 韩林霖, 匡雯雯, 孟瑶, 杨秀华. 超声引导衰减参数成像评估肝脂肪变性及其对心血管疾病风险的预测价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(08): 770-777.
[2] 赵亚楠, 方明, 徐绍岩, 魏树梅, 张慧, 黄奕宁, 刘亚静, 黄品同. 多声学技术参数联合血清学指标对非酒精性脂肪性肝病肝脂肪变性阶段的诊断价值[J/OL]. 中华医学超声杂志（电子版）, 2023, 20(11): 1164-1173.
[3] 万欣, 贺秋霞, 李明明, 王守志, 陈曦, 杨秀华. 超声衰减成像技术评价肝脂肪变性的相关因素分析[J/OL]. 中华医学超声杂志（电子版）, 2023, 20(01): 57-62.
[4] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[5] 程呈, 卢帅, 陈蓉, 李新萍, 白睿峰, 崔更力, 陈烁, 殷家伟, 胡建鹏, 汪垚卓, 蒋协远, 陈海翎. 基于基因表达数据库分析非酒精性脂肪性肝病炎症损伤相关核心基因[J/OL]. 中华损伤与修复杂志(电子版), 2025, 20(02): 99-106.
[6] 李敏, 杨世英, 高晓琴, 周丹, 唐筱, 张立婷. 维生素A与慢性肝病相关性研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(02): 65-70.
[7] 李嘉怡, 武楠. 基于基因表达数据库筛选牙周炎与非酒精性脂肪性肝炎的潜在共同关键基因[J/OL]. 中华口腔医学研究杂志(电子版), 2025, 19(03): 170-180.
[8] 汤鹏昊, 张武. 肠道微生态与肝移植围手术期并发症相关研究进展[J/OL]. 中华移植杂志(电子版), 2023, 17(05): 303-307.
[9] 王俊楠, 刘晔, 李若涵, 叶青松. 间充质干细胞调控肠脑轴治疗神经系统疾病的潜力[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 313-319.
[10] 王继才, 张广权, 吴芬芳, 史宪杰. 孟德尔随机化分析克罗恩病与非酒精性脂肪性肝病之间因果关系[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 601-608.
[11] 赵阳, 袁筑慧, 周林, 寇建涛, 郎韧, 贺强, 马军. 非酒精性脂肪性肝病肝癌和病毒性肝炎肝癌肝切除围手术期疗效和安全性的对比分析[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(03): 402-407.
[12] 徐涵治, 邱洵, 汪恺, 徐骁. 脂肪变性供肝脱脂策略的研究[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 18-24.
[13] 江浩, 余宏圣, 杨碧兰, 阿布都克尤木·斯马依, 吴斌, 杨逸冬. 基于列线图模型对慢性乙型肝炎合并肝脏脂肪变性患者并发晚期肝纤维化的临床预测[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 114-120.
[14] 白璐, 李青霞, 冯一卓, 刘雪倩, 刘若琪, 曲卓敏, 赵凌霞. 丁酸盐治疗糖尿病肾病的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(03): 303-308.
[15] 张杨杨, 项楚淇, 朱满生. 肌少性肥胖与非酒精性脂肪性肝病间的关系以及研究进展[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(04): 276-282.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号